Sanjay Kumar Dehury
About
Sanjay Kumar Dehury is from 印度 特伦甘纳邦 海得拉巴. Sanjay Kumar works in the following industries: "制药". Sanjay Kumar is currently Chief Scientific Officer at Formel Labs Pvt Ltd, located in Hyderabad, Telangana, India. In Sanjay Kumar's previous role as a Asst Vice President and Head-CRD (API and CRAMS) at Innovare Labs Pvt. Ltd, Sanjay Kumar worked in Hyderabad, Telangana, India until Jun 2021. Prior to joining Innovare Labs Pvt. Ltd, Sanjay Kumar was a General Manager and Head-API R&D at Ind-Swift-Laboratories Ltd. and held the position of General Manager and Head-API R&D at Chandīgarh Area, India. Prior to that, Sanjay Kumar was a Deputy General Manager and Head-API R&D at Ind-Swift-Laboratories Ltd., based in Chandigarh, India from Nov 2017 to Mar 2018. Sanjay Kumar started working as Deputy General Manager-API R&D at Ind-Swift-Laboratories Ltd. in Chandigarh, India in Jul 2017. From Apr 2015 to Jul 2017, Sanjay Kumar was Assistant General Manager- Oncology and antidiabetic R&D at Laurus Labs Limited, based in Hyderabad Area, India. Prior to that, Sanjay Kumar was a Senior Manager-Oncology R&D at Laurus Labs Limited, based in ICICI Knowledge Park, Hyderabad Area, India from Apr 2012 to Mar 2015. Sanjay Kumar started working as Manager- Oncology R&D at Laurus Labs Limited in Hyderabad Area, India in Nov 2010.
You can find Sanjay Kumar Dehury's email address at finalscout.com. FinalScout is a free professional database with over five hundred million business professional profiles and over two hundred million company profiles.
Sanjay Kumar Dehury's current jobs
> Currently with Formel Labs Pvt limited as CSO and Site Head > Leading chemical R&D (CRD), analytical R&D (ARD), developmental QA (DQA) and Technology Transfer (TT) > Responsible for overall scientific and technology development and scale up/commercialisation > Oversees regulatory filling and approval > Stakeholder of Site BU and overall organisation P&L
Sanjay Kumar Dehury's past jobs
> Assisted in turning the start-up profitable in 3rd year of commercial operation > Led Chemical R&D Division comprising of a team 45 scientists > Built strategic marketing strategy and revenue plan for the establishment of the vertical, and engaged with the buildout and construction of this formal organisation. > Assisted in control of variable and other costs to project real-world P&L statement from lab development till commercialisation. > Collaborated with manufacturing, quality, regulatory and supply chain; prioritisation of features and alignment to in-market strategy. > Worked with customers to gain stakeholder feedback about how services can solve problems each particular product > Led team for development and commercialisation of NCE and COVID-19 advanced intermediates > Led regulatory team filling of several drug master files during initial phase of operation > Ensured norms of Quality by Design (QbD) during process development > Established process robustness by evaluating critical process parameter (CPP), Design of Experiment (DoE) and Quality Risk Management (QRM)
> Led API-R&D Division with a team of 35 scientists to develop in-house as well as CRAMs API projects by co-ordinating with all the relavant stake-holders > Directed process optimization for in-house API products such as Ivabradine, Olmesartan and Ibrutinib. > Actively led Ind-swift team while interactive with customers for CRAMs projects > Provided assistance to multiple clients across the globe such as Kongo Pharmaceuticals, Nissan Chemicals and Pharmathen > Involved in the process optimization and contract manufacturing of API intermediates viz., Ezetimibe, and APIs such as Ropinirole, Valganciclovir and Metaraminol for privileged clients. > Managed the entire product development including requirement analysis, finalising specifications, validating designs, prototype development and component testing activities > Managed Setting up, calibrating, operating and maintaining a variety of laboratory and/or field research equipment as specified by the requirements of the research study > Monitored carryover of critical and Genotoxic Impurities (GTIs) and control thereof by ensuring purging factor evaluation
> Directed API process development projects of oncology and anti-diabetic type 2 therapeutic categories with 25 scientists > Merit of holding 14 patent applications filed on the process development of APIs and intermediates thereof > Formulated prep HPLC techniques for plant validation of high potent APIs > Provided assistance to multiple customers for P-IV filling of APIs viz., Cabazitaxel and Carfilzomib Submitted all required documents to Regulatory Team during various stages of development for filling of drug master file and supporting filling of several DMFs > Achieved indigenous development and/or commercialization of 10 products such as Carfilzomib, Pazopanib, Dapagliflozin, Empagliflozin, Cabazitaxel, Sunitinib, Docetaxel, Cisplatin, Carboplatin and Oxaliplatin, > Took part in many National & International technology events and product strategy workshops to understand future technology & product needs
> Led three projects at a given times with a team of 12 scientists > Inventor of 4 patents > Developed non-infringing, cost –effective, patented process for the APIs and API intermediates viz., Posaconazole, Voriconazole, Nateglinide and Rufinamide. > Project Manager: Interaction with interdisciplinary teams such as AR&D, DQA, IPM, SCM and Tech Transfer on regular basis for troubleshooting and planning/ managing of the projects
> Developed Indo-US Green Chemistry Network Center (GCNC) Award winning technology associated to conversion of a pollutant of Ranitidine process to a solvent (DMSO). > Co-author of an international publications and 6 patents > Developed process for APIs and intermediate viz., Eletripton, Sumatripton, Valsartan, Solifenacine, Bicalutamide, Ranitidine, Nizatidine, Paclitaxel side chain, docetaxel side chain and Diltiazem. > Successfully Guided multidisciplinary teams of 10 Scientists (Process development, CRO and IPM)
• Led projects with 6 scientists • Developed non-infringing cost –effective process for the APIs and API intermediates.